ID   ARSB_HUMAN              Reviewed;         533 AA.
AC   P15848; B2RC20; Q8N322; Q9UDI9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   18-JUN-2025, entry version 227.
DE   RecName: Full=Arylsulfatase B;
DE            Short=ASB;
DE            EC=3.1.6.12;
DE   AltName: Full=N-acetylgalactosamine-4-sulfatase;
DE            Short=G4S;
DE   Flags: Precursor;
GN   Name=ARSB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 103-119;
RP   135-158; 161-168; 286-295; 319-337; 379-387; 389-410; 440-450; 490-501;
RP   508-520 AND 525-533.
RC   TISSUE=Placenta, and Testis;
RX   PubMed=2303452; DOI=10.1016/s0021-9258(19)39778-9;
RA   Peters C., Schmidt B., Rommerskirch W., Rupp K., Zuehlsdorf M., Vingron M.,
RA   Meyer H.E., Pohlmann R., von Figura K.;
RT   "Phylogenetic conservation of arylsulfatases. cDNA cloning and expression
RT   of human arylsulfatase B.";
RL   J. Biol. Chem. 265:3374-3381(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1968043; DOI=10.1016/0888-7543(90)90460-c;
RA   Schuchman E.H., Jackson C.E., Desnick R.J.;
RT   "Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length
RT   cDNA, and regions of amino acid identity with arylsulfatases A and C.";
RL   Genomics 6:149-158(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-358.
RX   PubMed=7687847; DOI=10.1515/bchm3.1993.374.1-6.327;
RA   Modaressi S., Rupp K., von Figura K., Peters C.;
RT   "Structure of the human arylsulfatase B gene.";
RL   Biol. Chem. Hoppe-Seyler 374:327-335(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT MET-358.
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-104.
RX   PubMed=1930244;
RA   Litjens T., Morris C.P., Gibson G.J., Beckmann K.R., Hopwood J.J.;
RT   "Human N-acetylgalactosamine-4-sulphatase: protein maturation and isolation
RT   of genomic clones.";
RL   Biochem. Int. 24:209-215(1991).
RN   [9]
RP   PROTEIN SEQUENCE OF 41-55; 424-454 AND 466-483.
RC   TISSUE=Placenta;
RX   PubMed=1390929; DOI=10.1016/0167-4838(92)90051-e;
RA   Kobayashi T., Honke K., Jin T., Gasa S., Miyazaki T., Makita A.;
RT   "Components and proteolytic processing sites of arylsulfatase B from human
RT   placenta.";
RL   Biochim. Biophys. Acta 1159:243-247(1992).
RN   [10]
RP   OXOALANINE AT CYS-91, IDENTIFICATION BY MASS SPECTROMETRY, AND ABSENCE OF
RP   OXOALANINE IN MSD.
RX   PubMed=7628016; DOI=10.1016/0092-8674(95)90314-3;
RA   Schmidt B., Selmer T., Ingendoh A., von Figura K.;
RT   "A novel amino acid modification in sulfatases that is defective in
RT   multiple sulfatase deficiency.";
RL   Cell 82:271-278(1995).
RN   [11]
RP   INVOLVEMENT IN MSD.
RX   PubMed=15146462; DOI=10.1002/humu.20040;
RA   Cosma M.P., Pepe S., Parenti G., Settembre C., Annunziata I.,
RA   Wade-Martins R., Domenico C.D., Natale P.D., Mankad A., Cox B., Uziel G.,
RA   Mancini G.M., Zammarchi E., Donati M.A., Kleijer W.J., Filocamo M.,
RA   Carrozzo R., Carella M., Ballabio A.;
RT   "Molecular and functional analysis of SUMF1 mutations in multiple sulfatase
RT   deficiency.";
RL   Hum. Mutat. 23:576-581(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=19306108; DOI=10.1007/s10585-009-9253-z;
RA   Bhattacharyya S., Tobacman J.K.;
RT   "Arylsulfatase B regulates colonic epithelial cell migration by effects on
RT   MMP9 expression and RhoA activation.";
RL   Clin. Exp. Metastasis 26:535-545(2009).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-366.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=9032078; DOI=10.1016/s0969-2126(97)00185-8;
RA   Bond C.S., Clements P.R., Ashby S.J., Collyer C.A., Harrop S.J.,
RA   Hopwood J.J., Guss J.M.;
RT   "Structure of a human lysosomal sulfatase.";
RL   Structure 5:277-289(1997).
RN   [16]
RP   VARIANT MPS6 VAL-137, AND VARIANT MET-376.
RX   PubMed=1718978; DOI=10.1016/s0021-9258(18)54649-4;
RA   Wicker G., Prill V., Brooks D.A., Gibson G.J., Hopwood J.J., von Figura K.,
RA   Peters C.;
RT   "Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate
RT   clinical phenotype caused by substitution of valine for glycine at position
RT   137 of arylsulfatase B.";
RL   J. Biol. Chem. 266:21386-21391(1991).
RN   [17]
RP   VARIANTS MPS6 ARG-117; PRO-236 AND TYR-405.
RX   PubMed=1550123;
RA   Jin W.-D., Jackson C.E., Desnick R.J., Schuchman E.H.;
RT   "Mucopolysaccharidosis type VI: identification of three mutations in the
RT   arylsulfatase B gene of patients with the severe and mild phenotypes
RT   provides molecular evidence for genetic heterogeneity.";
RL   Am. J. Hum. Genet. 50:795-800(1992).
RN   [18]
RP   VARIANTS MPS6 ARG-144; ARG-192; PRO-321 AND TYR-521, AND CHARACTERIZATION
RP   OF VARIANTS MPS6.
RX   PubMed=8116615;
RA   Isbrandt D., Arlt G., Brooks D.A., Hopwood J.J., von Figura K., Peters C.;
RT   "Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique
RT   arylsulfatase B gene alleles causing variable disease phenotypes.";
RL   Am. J. Hum. Genet. 54:454-463(1994).
RN   [19]
RP   VARIANTS MPS6 TRP-152 AND GLN-160.
RX   PubMed=8125475; DOI=10.1007/bf00212019;
RA   Voskoboeva E., Isbrandt D., von Figura K., Krasnopolskaya X., Peters C.;
RT   "Four novel mutant alleles of the arylsulfatase B gene in two patients with
RT   intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).";
RL   Hum. Genet. 93:259-264(1994).
RN   [20]
RP   VARIANTS MPS6 ILE-142; ARG-146; LEU-146 AND SER-146.
RX   PubMed=8541342; DOI=10.1016/0925-4439(95)00070-4;
RA   Simonaro C.M., Schuchman E.H.;
RT   "N-acetylgalactosamine-4-sulfatase: identification of four new mutations
RT   within the conserved sulfatase region causing mucopolysaccharidosis type
RT   VI.";
RL   Biochim. Biophys. Acta 1272:129-132(1995).
RN   [21]
RP   VARIANTS MPS6 MET-92; GLN-95; CYS-210; PRO-393 AND PRO-498.
RX   PubMed=8651289;
RA   Litjens T., Brooks D.A., Peters C., Gibson G.J., Hopwood J.J.;
RT   "Identification, expression, and biochemical characterization of N-
RT   acetylgalactosamine-4-sulfatase mutations and relationship with clinical
RT   phenotype in MPS6 patients.";
RL   Am. J. Hum. Genet. 58:1127-1134(1996).
RN   [22]
RP   VARIANT MPS-IV ARG-302.
RX   PubMed=10206678;
RX   DOI=10.1002/(sici)1098-1004(1998)11:5<410::aid-humu9>3.0.co;2-q;
RA   Villani G.R.D., Balzano N., Di Natale P.;
RT   "Two novel mutations of the arylsulfatase B gene in two Italian patients
RT   with severe form of mucopolysaccharidosis.";
RL   Hum. Mutat. 11:410-410(1998).
RN   [23]
RP   VARIANT MET-358.
RX   PubMed=9582121; DOI=10.1126/science.280.5366.1077;
RA   Wang D.G., Fan J.-B., Siao C.-J., Berno A., Young P., Sapolsky R.,
RA   Ghandour G., Perkins N., Winchester E., Spencer J., Kruglyak L., Stein L.,
RA   Hsie L., Topaloglou T., Hubbell E., Robinson E., Mittmann M., Morris M.S.,
RA   Shen N., Kilburn D., Rioux J., Nusbaum C., Rozen S., Hudson T.J.,
RA   Lipshutz R., Chee M., Lander E.S.;
RT   "Large-scale identification, mapping, and genotyping of single-nucleotide
RT   polymorphisms in the human genome.";
RL   Science 280:1077-1082(1998).
RN   [24]
RP   VARIANTS MPS6 PHE-65; HIS-116; GLN-315 AND ARG-531, AND VARIANT MET-358.
RX   PubMed=10036316; DOI=10.1016/s0925-4439(98)00099-4;
RA   Villani G.R.D., Balzano N., Vitale D., Saviano M., Pavone V., Di Natale P.;
RT   "Maroteaux-Lamy syndrome: five novel mutations and their structural
RT   localization.";
RL   Biochim. Biophys. Acta 1453:185-192(1999).
RN   [25]
RP   VARIANTS MPS6 ARG-192 AND ARG-239.
RX   PubMed=10738004;
RX   DOI=10.1002/(sici)1098-1004(200004)15:4<389::aid-humu31>3.0.co;2-0;
RA   Wu J.-Y., Yang C.-F., Lee C.-C., Chang J.-G., Tsai F.-J.;
RT   "A novel mutation (Q239R) identified in a Taiwan Chinese patient with type
RT   VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).";
RL   Hum. Mutat. 15:389-390(2000).
RN   [26]
RP   VARIANTS MPS6 ARG-192; ARG-239 AND LEU-399, AND VARIANT MET-358.
RX   PubMed=11802522;
RA   Yang C.-F., Wu J.-Y., Lin S.-P., Tsai F.-J.;
RT   "Mucopolysaccharidosis type VI: report of two Taiwanese patients and
RT   identification of one novel mutation.";
RL   J. Formos. Med. Assoc. 100:820-823(2001).
RN   [27]
RP   VARIANTS MPS6 TYR-86 DEL; CYS-210; PRO-236; CYS-312; GLN-315; PRO-321 AND
RP   GLY-484, VARIANTS MET-358; MET-376 AND ASN-384, AND CHARACTERIZATION OF
RP   VARIANTS MPS6 TYR-86 DEL AND CYS-312.
RX   PubMed=14974081; DOI=10.1002/humu.10313;
RA   Karageorgos L., Harmatz P., Simon J., Pollard A., Clements P.R.,
RA   Brooks D.A., Hopwood J.J.;
RT   "Mutational analysis of mucopolysaccharidosis type VI patients undergoing a
RT   trial of enzyme replacement therapy.";
RL   Hum. Mutat. 23:229-233(2004).
RN   [28]
RP   VARIANTS MPS6 ARG-82 AND GLN-315, AND VARIANT ASN-384.
RX   PubMed=19259130; DOI=10.1038/ejhg.2009.19;
RA   Zanetti A., Ferraresi E., Picci L., Filocamo M., Parini R., Rosano C.,
RA   Tomanin R., Scarpa M.;
RT   "Segregation analysis in a family at risk for the Maroteaux-Lamy syndrome
RT   conclusively reveals c.1151G>A (p.S384N) as to be a polymorphism.";
RL   Eur. J. Hum. Genet. 17:1160-1164(2009).
CC   -!- FUNCTION: Removes sulfate groups from chondroitin-4-sulfate (C4S) and
CC       regulates its degradation (PubMed:19306108). Involved in the regulation
CC       of cell adhesion, cell migration and invasion in colonic epithelium
CC       (PubMed:19306108). In the central nervous system, is a regulator of
CC       neurite outgrowth and neuronal plasticity, acting through the control
CC       of sulfate glycosaminoglycans and neurocan levels (By similarity).
CC       {ECO:0000250|UniProtKB:P50430, ECO:0000269|PubMed:19306108}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Hydrolysis of the 4-sulfate groups of the N-acetyl-D-
CC         galactosamine 4-sulfate units of chondroitin sulfate and dermatan
CC         sulfate.; EC=3.1.6.12;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 1 Ca(2+) ion per subunit.;
CC   -!- ACTIVITY REGULATION: Inhibited by ethanol (By similarity).
CC       {ECO:0000250|UniProtKB:P50430}.
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000250|UniProtKB:P50429}. Cell
CC       surface {ECO:0000250|UniProtKB:P50429}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15848-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15848-2; Sequence=VSP_042721;
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-formylglycine,
CC       FGly), of a serine or cysteine residue in prokaryotes and of a cysteine
CC       residue in eukaryotes, is critical for catalytic activity. This post-
CC       translational modification is severely defective in multiple sulfatase
CC       deficiency (MSD). {ECO:0000269|PubMed:7628016}.
CC   -!- DISEASE: Mucopolysaccharidosis 6 (MPS6) [MIM:253200]: A form of
CC       mucopolysaccharidosis, a group of lysosomal storage diseases
CC       characterized by defective degradation of glycosaminoglycans, resulting
CC       in their excessive accumulation and secretion. The diseases are
CC       progressive and often display a wide spectrum of clinical severity.
CC       MPS6 is an autosomal recessive form characterized by intracellular
CC       accumulation of dermatan sulfate. Clinical features can include
CC       abnormal growth, short stature, stiff joints, skeletal malformations,
CC       corneal clouding, hepatosplenomegaly, and cardiac abnormalities.
CC       {ECO:0000269|PubMed:10036316, ECO:0000269|PubMed:10738004,
CC       ECO:0000269|PubMed:11802522, ECO:0000269|PubMed:14974081,
CC       ECO:0000269|PubMed:1550123, ECO:0000269|PubMed:1718978,
CC       ECO:0000269|PubMed:19259130, ECO:0000269|PubMed:8116615,
CC       ECO:0000269|PubMed:8125475, ECO:0000269|PubMed:8541342,
CC       ECO:0000269|PubMed:8651289}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Multiple sulfatase deficiency (MSD) [MIM:272200]: A clinically
CC       and biochemically heterogeneous disorder caused by the simultaneous
CC       impairment of all sulfatases, due to defective post-translational
CC       modification and activation. It combines features of individual
CC       sulfatase deficiencies such as metachromatic leukodystrophy,
CC       mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus,
CC       ichthyosis, neurologic deterioration and developmental delay.
CC       {ECO:0000269|PubMed:15146462}. Note=The protein represented in this
CC       entry is involved in disease pathogenesis. Arylsulfatase B activity is
CC       impaired in multiple sulfatase deficiency due to mutations in SUMF1.
CC       SUMF1 mutations result in defective post-translational modification of
CC       ARSB at residue Cys-91 that is not converted to 3-oxoalanine.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J05225; AAA51784.1; -; mRNA.
DR   EMBL; M32373; AAA51779.1; -; mRNA.
DR   EMBL; X72735; CAA51272.1; -; Genomic_DNA.
DR   EMBL; X72736; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72737; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72738; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72739; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72740; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72741; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72742; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; AK314903; BAG37417.1; -; mRNA.
DR   EMBL; AC020937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025755; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC099485; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC114963; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471084; EAW95822.1; -; Genomic_DNA.
DR   EMBL; BC029051; AAH29051.1; -; mRNA.
DR   EMBL; S57777; AAB19988.1; -; Genomic_DNA.
DR   CCDS; CCDS4043.1; -. [P15848-1]
DR   CCDS; CCDS43334.1; -. [P15848-2]
DR   PIR; S35990; KJHUAB.
DR   RefSeq; NP_000037.2; NM_000046.3. [P15848-1]
DR   RefSeq; NP_942002.1; NM_198709.3. [P15848-2]
DR   RefSeq; XP_011541692.1; XM_011543390.2. [P15848-1]
DR   PDB; 1FSU; X-ray; 2.50 A; A=42-533.
DR   PDBsum; 1FSU; -.
DR   AlphaFoldDB; P15848; -.
DR   SMR; P15848; -.
DR   BioGRID; 106904; 45.
DR   FunCoup; P15848; 472.
DR   IntAct; P15848; 35.
DR   STRING; 9606.ENSP00000264914; -.
DR   ChEMBL; CHEMBL2399; -.
DR   DrugBank; DB09301; Chondroitin sulfate.
DR   GlyConnect; 1016; 3 N-Linked glycans (3 sites).
DR   GlyCosmos; P15848; 7 sites, 4 glycans.
DR   GlyGen; P15848; 7 sites, 17 N-linked glycans (4 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; P15848; -.
DR   PhosphoSitePlus; P15848; -.
DR   BioMuta; ARSB; -.
DR   jPOST; P15848; -.
DR   MassIVE; P15848; -.
DR   PaxDb; 9606-ENSP00000264914; -.
DR   PeptideAtlas; P15848; -.
DR   ProteomicsDB; 53228; -. [P15848-1]
DR   ProteomicsDB; 53229; -. [P15848-2]
DR   Pumba; P15848; -.
DR   Antibodypedia; 24535; 316 antibodies from 36 providers.
DR   DNASU; 411; -.
DR   Ensembl; ENST00000264914.10; ENSP00000264914.4; ENSG00000113273.17. [P15848-1]
DR   Ensembl; ENST00000396151.7; ENSP00000379455.3; ENSG00000113273.17. [P15848-2]
DR   GeneID; 411; -.
DR   KEGG; hsa:411; -.
DR   MANE-Select; ENST00000264914.10; ENSP00000264914.4; NM_000046.5; NP_000037.2.
DR   UCSC; uc003kfq.5; human. [P15848-1]
DR   AGR; HGNC:714; -.
DR   CTD; 411; -.
DR   DisGeNET; 411; -.
DR   GeneCards; ARSB; -.
DR   HGNC; HGNC:714; ARSB.
DR   HPA; ENSG00000113273; Low tissue specificity.
DR   MalaCards; ARSB; -.
DR   MIM; 253200; phenotype.
DR   MIM; 272200; phenotype.
DR   MIM; 611542; gene.
DR   OpenTargets; ENSG00000113273; -.
DR   Orphanet; 276212; Mucopolysaccharidosis type 6, rapidly progressing.
DR   Orphanet; 276223; Mucopolysaccharidosis type 6, slowly progressing.
DR   VEuPathDB; HostDB:ENSG00000113273; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   GeneTree; ENSGT00940000158270; -.
DR   HOGENOM; CLU_006332_10_1_1; -.
DR   InParanoid; P15848; -.
DR   OMA; HEHCVFI; -.
DR   OrthoDB; 103349at2759; -.
DR   PAN-GO; P15848; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; P15848; -.
DR   BioCyc; MetaCyc:HS03665-MONOMER; -.
DR   BRENDA; 3.1.6.1; 2681.
DR   BRENDA; 3.1.6.12; 2681.
DR   PathwayCommons; P15848; -.
DR   Reactome; R-HSA-1663150; The activation of arylsulfatases.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-2206285; MPS VI - Maroteaux-Lamy syndrome.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-9840310; Glycosphingolipid catabolism.
DR   SABIO-RK; P15848; -.
DR   SignaLink; P15848; -.
DR   BioGRID-ORCS; 411; 17 hits in 1161 CRISPR screens.
DR   ChiTaRS; ARSB; human.
DR   EvolutionaryTrace; P15848; -.
DR   GenomeRNAi; 411; -.
DR   Pharos; P15848; Tbio.
DR   PRO; PR:P15848; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P15848; protein.
DR   Bgee; ENSG00000113273; Expressed in calcaneal tendon and 120 other cell types or tissues.
DR   ExpressionAtlas; P15848; baseline and differential.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0004065; F:arylsulfatase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003943; F:N-acetylgalactosamine-4-sulfatase activity; IDA:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:Ensembl.
DR   GO; GO:0061580; P:colon epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0007041; P:lysosomal transport; TAS:ProtInc.
DR   GO; GO:0007040; P:lysosome organization; TAS:ProtInc.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0051597; P:response to methylmercury; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0009268; P:response to pH; IEA:Ensembl.
DR   CDD; cd16029; 4-S; 1.
DR   DisProt; DP02670; -.
DR   FunFam; 3.30.1120.10:FF:000002; Arylsulfatase family member J; 1.
DR   FunFam; 3.40.720.10:FF:000007; Arylsulfatase family, member J; 1.
DR   Gene3D; 3.30.1120.10; -; 1.
DR   Gene3D; 3.40.720.10; Alkaline Phosphatase, subunit A; 1.
DR   InterPro; IPR017850; Alkaline_phosphatase_core_sf.
DR   InterPro; IPR047115; ARSB.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   PANTHER; PTHR10342; ARYLSULFATASE; 1.
DR   PANTHER; PTHR10342:SF274; ARYLSULFATASE B; 1.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; Alkaline phosphatase-like; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
DR   neXtProt; NX_P15848; -.
DR   PharmGKB; PA25006; -.
DR   TreeFam; TF314186; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Glycoprotein; Hydrolase; Ichthyosis;
KW   Leukodystrophy; Lysosome; Metachromatic leukodystrophy; Metal-binding;
KW   Mucopolysaccharidosis; Proteomics identification; Reference proteome;
KW   Signal.
FT   SIGNAL          1..36
FT                   /note="Or 38"
FT                   /evidence="ECO:0000255"
FT   CHAIN           37..533
FT                   /note="Arylsulfatase B"
FT                   /id="PRO_0000033421"
FT   ACT_SITE        91
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:7628016"
FT   ACT_SITE        147
FT   BINDING         53
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         54
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         91
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /note="via 3-oxoalanine"
FT                   /evidence="ECO:0000269|PubMed:7628016"
FT   BINDING         145
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         242
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         300
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         301
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         318
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         91
FT                   /note="3-oxoalanine (Cys)"
FT                   /evidence="ECO:0000269|PubMed:7628016"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        279
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        291
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        366
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        426
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        458
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        117..521
FT   DISULFID        121..155
FT   DISULFID        181..192
FT   DISULFID        405..447
FT   VAR_SEQ         405..533
FT                   /note="CPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQ
FT                   YNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFP
FT                   AQDPRCDPKATGVWGPWM -> YWPECSLLL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042721"
FT   VARIANT         65
FT                   /note="S -> F (in MPS6; intermediate form;
FT                   dbSNP:rs1233331806)"
FT                   /evidence="ECO:0000269|PubMed:10036316"
FT                   /id="VAR_019017"
FT   VARIANT         82
FT                   /note="L -> R (in MPS6; dbSNP:rs749465732)"
FT                   /evidence="ECO:0000269|PubMed:19259130"
FT                   /id="VAR_080270"
FT   VARIANT         86
FT                   /note="Missing (in MPS6; severe form; low protein levels
FT                   and activity; dbSNP:rs969231209)"
FT                   /evidence="ECO:0000269|PubMed:14974081"
FT                   /id="VAR_019018"
FT   VARIANT         92
FT                   /note="T -> M (in MPS6; mild form; dbSNP:rs751010538)"
FT                   /evidence="ECO:0000269|PubMed:8651289"
FT                   /id="VAR_007294"
FT   VARIANT         95
FT                   /note="R -> Q (in MPS6; mild/severe form;
FT                   dbSNP:rs118203942)"
FT                   /evidence="ECO:0000269|PubMed:8651289"
FT                   /id="VAR_007295"
FT   VARIANT         116
FT                   /note="P -> H (in MPS6; severe form; dbSNP:rs775780931)"
FT                   /evidence="ECO:0000269|PubMed:10036316"
FT                   /id="VAR_019019"
FT   VARIANT         117
FT                   /note="C -> R (in MPS6; severe form; dbSNP:rs118203939)"
FT                   /evidence="ECO:0000269|PubMed:1550123"
FT                   /id="VAR_007296"
FT   VARIANT         137
FT                   /note="G -> V (in MPS6; intermediate form;
FT                   dbSNP:rs118203938)"
FT                   /evidence="ECO:0000269|PubMed:1718978"
FT                   /id="VAR_007297"
FT   VARIANT         142
FT                   /note="M -> I (in MPS6; dbSNP:rs1554088053)"
FT                   /evidence="ECO:0000269|PubMed:8541342"
FT                   /id="VAR_019020"
FT   VARIANT         144
FT                   /note="G -> R (in MPS6; severe form; severe reduction of
FT                   activity; dbSNP:rs746206847)"
FT                   /evidence="ECO:0000269|PubMed:8116615"
FT                   /id="VAR_019021"
FT   VARIANT         146
FT                   /note="W -> L (in MPS6; dbSNP:rs1554088034)"
FT                   /evidence="ECO:0000269|PubMed:8541342"
FT                   /id="VAR_019022"
FT   VARIANT         146
FT                   /note="W -> R (in MPS6; dbSNP:rs1554088037)"
FT                   /evidence="ECO:0000269|PubMed:8541342"
FT                   /id="VAR_019023"
FT   VARIANT         146
FT                   /note="W -> S (in MPS6; dbSNP:rs1554088034)"
FT                   /evidence="ECO:0000269|PubMed:8541342"
FT                   /id="VAR_019024"
FT   VARIANT         152
FT                   /note="R -> W (in MPS6; intermediate form;
FT                   dbSNP:rs991104525)"
FT                   /evidence="ECO:0000269|PubMed:8125475"
FT                   /id="VAR_007298"
FT   VARIANT         160
FT                   /note="R -> Q (in MPS6; intermediate form;
FT                   dbSNP:rs1196325597)"
FT                   /evidence="ECO:0000269|PubMed:8125475"
FT                   /id="VAR_007299"
FT   VARIANT         192
FT                   /note="C -> R (in MPS6; mild form; severe reduction of
FT                   activity; dbSNP:rs1554087423)"
FT                   /evidence="ECO:0000269|PubMed:10738004,
FT                   ECO:0000269|PubMed:11802522, ECO:0000269|PubMed:8116615"
FT                   /id="VAR_019025"
FT   VARIANT         210
FT                   /note="Y -> C (in MPS6; mild/intermediate;
FT                   dbSNP:rs118203943)"
FT                   /evidence="ECO:0000269|PubMed:14974081,
FT                   ECO:0000269|PubMed:8651289"
FT                   /id="VAR_007300"
FT   VARIANT         236
FT                   /note="L -> P (in MPS6; mild form; dbSNP:rs118203940)"
FT                   /evidence="ECO:0000269|PubMed:14974081,
FT                   ECO:0000269|PubMed:1550123"
FT                   /id="VAR_007301"
FT   VARIANT         239
FT                   /note="Q -> R (in MPS6; dbSNP:rs1554086431)"
FT                   /evidence="ECO:0000269|PubMed:10738004,
FT                   ECO:0000269|PubMed:11802522"
FT                   /id="VAR_019026"
FT   VARIANT         302
FT                   /note="G -> R (in MPS6; severe form; dbSNP:rs779378413)"
FT                   /evidence="ECO:0000269|PubMed:10206678"
FT                   /id="VAR_007302"
FT   VARIANT         312
FT                   /note="W -> C (in MPS6; severe form; loss of activity;
FT                   dbSNP:rs759384989)"
FT                   /evidence="ECO:0000269|PubMed:14974081"
FT                   /id="VAR_019027"
FT   VARIANT         315
FT                   /note="R -> Q (in MPS6; intermediate form;
FT                   dbSNP:rs727503809)"
FT                   /evidence="ECO:0000269|PubMed:10036316,
FT                   ECO:0000269|PubMed:14974081, ECO:0000269|PubMed:19259130"
FT                   /id="VAR_019028"
FT   VARIANT         321
FT                   /note="L -> P (in MPS6; intermediate form; severe reduction
FT                   of activity; dbSNP:rs1554079320)"
FT                   /evidence="ECO:0000269|PubMed:14974081,
FT                   ECO:0000269|PubMed:8116615"
FT                   /id="VAR_019029"
FT   VARIANT         358
FT                   /note="V -> L (in dbSNP:rs1065757)"
FT                   /id="VAR_061883"
FT   VARIANT         358
FT                   /note="V -> M (in dbSNP:rs1065757)"
FT                   /evidence="ECO:0000269|PubMed:10036316,
FT                   ECO:0000269|PubMed:11802522, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:14974081, ECO:0000269|PubMed:7687847,
FT                   ECO:0000269|PubMed:9582121"
FT                   /id="VAR_016061"
FT   VARIANT         376
FT                   /note="V -> M (in dbSNP:rs1071598)"
FT                   /evidence="ECO:0000269|PubMed:14974081,
FT                   ECO:0000269|PubMed:1718978"
FT                   /id="VAR_007303"
FT   VARIANT         384
FT                   /note="S -> N (in dbSNP:rs25414)"
FT                   /evidence="ECO:0000269|PubMed:14974081,
FT                   ECO:0000269|PubMed:19259130"
FT                   /id="VAR_019030"
FT   VARIANT         393
FT                   /note="H -> P (in MPS6; mild/severe form;
FT                   dbSNP:rs118203944)"
FT                   /evidence="ECO:0000269|PubMed:8651289"
FT                   /id="VAR_007304"
FT   VARIANT         399
FT                   /note="F -> L (in MPS6; dbSNP:rs200793396)"
FT                   /evidence="ECO:0000269|PubMed:11802522"
FT                   /id="VAR_019031"
FT   VARIANT         405
FT                   /note="C -> Y (in MPS6; mild form; dbSNP:rs118203941)"
FT                   /evidence="ECO:0000269|PubMed:1550123"
FT                   /id="VAR_007305"
FT   VARIANT         484
FT                   /note="R -> G (in MPS6; dbSNP:rs201101343)"
FT                   /evidence="ECO:0000269|PubMed:14974081"
FT                   /id="VAR_019032"
FT   VARIANT         498
FT                   /note="L -> P (in MPS6; mild/severe form;
FT                   dbSNP:rs774358117)"
FT                   /evidence="ECO:0000269|PubMed:8651289"
FT                   /id="VAR_007306"
FT   VARIANT         521
FT                   /note="C -> Y (in MPS6; severe form; severe reduction of
FT                   activity; dbSNP:rs1554069661)"
FT                   /evidence="ECO:0000269|PubMed:8116615"
FT                   /id="VAR_019033"
FT   VARIANT         531
FT                   /note="P -> R (in MPS6; mild form; dbSNP:rs1554069659)"
FT                   /evidence="ECO:0000269|PubMed:10036316"
FT                   /id="VAR_019034"
FT   CONFLICT        153
FT                   /note="K -> F (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        408..410
FT                   /note="NSM -> SPC (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          46..54
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           61..63
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           70..77
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          79..82
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           91..100
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           104..107
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           129..135
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          139..144
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           153..155
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           157..159
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          163..167
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          169..171
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   TURN            175..177
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          179..184
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   TURN            185..188
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          189..194
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           211..224
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          232..237
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          242..244
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           249..251
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           253..255
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           261..286
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           290..292
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          293..301
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           305..307
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          320..322
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           323..326
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          330..333
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          341..344
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           353..360
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           377..382
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          390..396
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          429..435
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          438..443
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   TURN            454..456
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   STRAND          472..476
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   TURN            477..479
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   TURN            488..490
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           492..507
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   HELIX           519..521
FT                   /evidence="ECO:0007829|PDB:1FSU"
FT   TURN            524..526
FT                   /evidence="ECO:0007829|PDB:1FSU"
SQ   SEQUENCE   533 AA;  59687 MW;  5983FB6911C4789A CRC64;
     MGPRGAASLP RGPGPRRLLL PVVLPLLLLL LLAPPGSGAG ASRPPHLVFL LADDLGWNDV
     GFHGSRIRTP HLDALAAGGV LLDNYYTQPL CTPSRSQLLT GRYQIRTGLQ HQIIWPCQPS
     CVPLDEKLLP QLLKEAGYTT HMVGKWHLGM YRKECLPTRR GFDTYFGYLL GSEDYYSHER
     CTLIDALNVT RCALDFRDGE EVATGYKNMY STNIFTKRAI ALITNHPPEK PLFLYLALQS
     VHEPLQVPEE YLKPYDFIQD KNRHHYAGMV SLMDEAVGNV TAALKSSGLW NNTVFIFSTD
     NGGQTLAGGN NWPLRGRKWS LWEGGVRGVG FVASPLLKQK GVKNRELIHI SDWLPTLVKL
     ARGHTNGTKP LDGFDVWKTI SEGSPSPRIE LLHNIDPNFV DSSPCPRNSM APAKDDSSLP
     EYSAFNTSVH AAIRHGNWKL LTGYPGCGYW FPPPSQYNVS EIPSSDPPTK TLWLFDIDRD
     PEERHDLSRE YPHIVTKLLS RLQFYHKHSV PVYFPAQDPR CDPKATGVWG PWM
//
